Kura Oncology, Inc. (KURA): Price and Financial Metrics


Kura Oncology, Inc. (KURA)

Today's Latest Price: $16.87 USD

0.63 (3.88%)

Updated Jun 5 4:00pm

Add KURA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

KURA Daily Price Range
KURA 52-Week Price Range

KURA Stock Price Chart More Charts


KURA Price/Volume Stats

Current price $16.87 52-week high $21.42
Prev. close $16.24 52-week low $6.35
Day low $16.49 Volume 535,371
Day high $17.29 Avg. volume 520,673
50-day MA $13.05 Dividend yield N/A
200-day MA $13.58 Market Cap 766.52M

Kura Oncology, Inc. (KURA) Company Bio


Kura Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. The company was founded in 2014 and is based in La Jolla, California.


KURA Latest News Stream


Event/TimeNews Detail
Loading, please wait...

KURA Latest Social Stream


Loading social stream, please wait...

View Full KURA Social Stream

Latest KURA News From Around the Web

Below are the latest news stories about Kura Oncology Inc that investors may wish to consider to help them evaluate KURA as an investment opportunity.

Kura Oncology Reports Overall Survival Data from Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinoma

Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced updated clinical outcome data from its RUN-HN study, a Phase 2 open-label, single-arm trial of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) whose disease had progressed after prior therapy. A copy of the presentation is available on Kura's website at www.kuraoncology.com/pipeline/publications.

Yahoo | May 29, 2020

Kura Oncology Announces Three Abstracts Accepted for Presentation at ASCO20 Virtual Scientific Program

Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that three abstracts highlighting its drug candidate tipifarnib have been accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) Virtual Scientific Program, to be held May 29-31, 2020. “We are pleased to announce the presentation of three clinical abstracts for tipifarnib, including an oral presentation highlighting single-agent activity in multiple solid tumors with HRAS mutations,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

Yahoo | May 13, 2020

Edited Transcript of KURA earnings conference call or presentation 4-May-20 8:30pm GMT

Q1 2020 Kura Oncology Inc Earnings Call

Yahoo | May 13, 2020

Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

SAN DIEGO, May 08, 2020 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the.

Yahoo | May 8, 2020

Kura Oncology to Present at BofA Securities Virtual Health Care Conference 2020

Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the BofA Securities Virtual Healthcare Conference 2020. Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.

Yahoo | May 7, 2020

Read More 'KURA' Stories Here

KURA Price Returns

1-mo 15.39%
3-mo 53.36%
6-mo 7.45%
1-year -2.37%
3-year 98.47%
5-year N/A
YTD 22.69%
2019 -2.07%
2018 -8.24%
2017 159.32%
2016 -29.76%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7475 seconds.